Melphalan Sensitivity in Mouse Mammary Tumors
Author Information
Author(s): B.E. Miller, F.R. Miller, T. Machemer, G.H. Heppner
Primary Institution: Meyer L. Prentis Comprehensive Cancer Center of Metropolitan Detroit
Hypothesis
How does melphalan sensitivity vary with metastatic growth in mouse mammary tumor subpopulations?
Conclusion
The study found that different subpopulations of tumor cells respond differently to melphalan at various stages of metastasis.
Supporting Evidence
- Both cell lines were similarly sensitive to melphalan at early times after injection but became less sensitive at later times.
- Line 4T07 showed a marked reduction in sensitivity at later stages compared to line 66FAR.
- In vivo measures of tumor sensitivity did not predict changes in sensitivity observed in vitro.
Takeaway
This study looked at how well two types of cancer cells respond to a medicine called melphalan at different stages of cancer growth, finding that they react differently depending on how advanced the cancer is.
Methodology
The study used mouse mammary tumor cell lines treated with melphalan in vivo and measured their sensitivity through colony-forming assays.
Limitations
The study did not analyze the time course of growth of untreated line 66FAR cells in the lung.
Participant Demographics
Male BALB/c mice aged 8 to 12 weeks were used in the experiments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website